Bottom line
Is DRGY a good fund? The bottom line
DRGY is a managed options & covered-call income ETF from YieldMax.
It charges 0.99% — about $99 a year on every $10,000 invested, more expensive than 63% of options & covered-call income funds we track.
Updated Nov 19, 2026
What DRGY invests in
The Funds primary investment objective is to seek current income.
The Fund is an actively managed exchange-traded fund (ETF) that seeks (i) to generate cash distributions, and (ii) capital appreciation. The Funds strategy involves: (1) constructing a portfolio of U.S.-listed equity securities of Biotech and Pharma Companies (each, an Underlying Security) (the Equity Strategy) and (2) the use of options strategies designed to generate premiums (the Options Strategies), which involve using options contracts on Underlying Securities and/or Biotech and Pharma ETFs (described below). The Fund will also maintain a minor allocation to cash or U.S. Treasuries, not exceeding ten percent of its total assets. Equity Strategy The Adviser selects the Biotech and Pharma Companies in which the Fund will invest. Biotech and Pharma Companies are companies involved in the research, development, manufacturing, and commercialization of biotechnological and…
From the fund's prospectus (filed Nov 21, 2025).
What DRGY costs
On a $10,000 investment, DRGY's 0.99% expense ratio costs about $99 a year. The median options & covered-call income fund charges 0.99%.